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Use of neoadjuvant chemotherapy (NAC) has expanded over the past several years and is currently considered an alternative to adjuvant chemotherapy for selected patients with operable breast cancer. 1 Development of more active NAC regimens (with or without addition of biologics) and improvements in patient selection for NAC based on tumor subtype have resulted in increasing rates of pathologic complete response (pCR) in the breast and axilla. 1 In addition, improvements in breast imaging have enhanced our ability to identify preoperatively patients who are likely to have achieved pCR following NAC. For such patients, an emerging but yet unanswered question is whether formal surgical resection of the area of the tumor bed in the breast is necessary as part of breast-conserving therapy or whether it could safely be omitted. Before the question of omission of formal surgical resection in the breast can be addressed, studies have to identify a reliable and reproducible approach by which patients at high likelihood of pCR can be identified preoperatively.
Traditionally, tumor assessment for preoperative prediction of pCR is based on clinical examination and imaging studies. Clinical examination has historically shown low sensitivity in predicting pCR, but this could also be attributed to the overall low rate of pcR in early series and randomized clinical trials of NAC; For example, in the NSABP B-18 trial, only 26% of patients who had clinical complete response by clinical examination had pCR. The ability to predict pCR clearly improves when incorporating preoperative imaging studies. Conventional imaging modalities, such as mammography and breast ultrasound, have limited accuracy in predicting pCR, [2] [3] [4] but this improves with addition of breast magnetic resonance imaging (MRI). [5] [6] [7] [8] [9] [10] However, even with trimodality imaging (mammogram, ultrasound, and MRI), the negative predictive value for pCR is generally under 90%, [9] [10] [11] leading to the conclusion that neither breast MRI nor mammogram or breast ultrasound can preoperatively identify pCR with sufficient accuracy to replace pathologic diagnosis of the surgical excision specimen. 9 Recently, interest has developed in evaluating imageguided biopsy of the tumor bed in order to enhance the accuracy of predicting pCR in patients who have clinically complete and radiologically complete/near-complete response to NAC. This approach has the potential to more accurately identify optimal candidates for possible omission of primary tumor surgical excision for patients who intend to be treated with breast-conserving therapy.
In this issue of the journal, Rauch et al. from MD Anderson Cancer Center present the secondary imaging endpoints of a trial that evaluated mammography, breast ultrasound, and image-guided biopsy of the tumor bed for assessment of pCR in breast cancer patients undergoing NAC. 12 Forty patients with T1-3, N0-3, M0 triple-negative or human epidermal growth factor receptor 2 (HER2)-positive breast cancer who received NAC underwent mammogram and breast ultrasound at baseline and after NAC. Images were evaluated for residual abnormality and to determine the best modality for image-guided biopsy (ultrasound guided or stereotactic guided). Fine-needle aspiration and 9-gauge vacuum-assisted core biopsy (VACB) of the tumor bed were performed after NAC and compared with histopathology at surgery. Nineteen patients had pCR, of whom 12 (63%) had some residual imaging abnormality presurgery (residual calcifications: 6; residual mass: 5; both: 1). The sensitivity, specificity, and accuracy of ultrasound, mammogram, and image-guided VACB for pCR were 47/95/73%, 53/90/73%, and 100/95/98%, respectively. Twenty-five patients had stereotactic VACB, and 15 had ultrasound-guided VACB. The median number of cores was higher with stereotactic VACB (12, range 6-14) than with ultrasound-guided VACB (8, range 4-12; p \ 0.002). The positive predictive value for pCR was significantly higher for stereotactic-than for ultrasoundguided VACB (100 vs 60%, p \ 0.05). Based on these findings, the authors conclude that stereotactic VACB is the preferred image-guided biopsy method for identifying patients with pCR for trials testing the safety of omitting formal surgical resection of the primary tumor bed.
The results by Rauch et al. indicate that, following complete clinical and complete/near-complete radiologic response, stereotactic VACB can accurately identify patients who have pCR but ultrasound-guided VACB is considerably less accurate. These findings are based on a relatively small number of patients and should be interpreted with caution. Moreover, whether the observed differences in accuracy are related to differences in technique between the two approaches or are merely the result of differences in the number of cores obtained with each approach remains to be determined. Of interest, both cases of false-negative findings by ultrasound-guided VACB in the study by Rauch et al. occurred in patents with a low number of cores (four and six). Similar findings have been observed in other studies. 13, 14 In a multicenter pooled analysis of prospectively assembled data by the German Breast Group that predominantly used ultrasound-guided core biopsies in 164 patients with clinical complete response after NAC and did not include complete radiographic response using standardized imaging criteria for patient selection for biopsy, the negative predictive value for pCR was 71% and the false-negative rate was 49%. 13 However, when mammographic-guided VACB was performed, the negative predictive value was 100% with a false-negative rate of 0%. 13 In the small NOSTRA PRE-LIM trial, 14 20 patients with operable primary breast cancer scheduled for NAC underwent ultrasound-guided core biopsy (median 4 cores, range 2-6) followed by surgery. All tumor subtypes were included. Residual disease was correctly identified in 16/20 patients, and all these patients had three core biopsies.
14 As a result, a follow-up larger trial from the same group that will include 150 participants with triple-negative or HER2-positive breast cancer is designed to both take more biopsies (minimum six ultrasound-guided biopsies) and also sample a larger area of the tumor bed in order to minimize the false-negative rate (NOSTRA Feasibility Trial). 15 The study by Rauch et al. did not include breast MRI in the assessment of radiologic response after NAC. 12 As mentioned above, mammography and breast ultrasound have limited accuracy in predicting pCR, 2-4 which can be improved by addition of breast MRI. [5] [6] [7] [8] In fact, the study by Rauch et al. confirmed the low accuracy of mammography and ultrasound in predicting pCR after NAC (73 and 73%, respectively), but whether addition of VACB would increase the negative predictive value of imaging assessment that includes MR remains to be seen. On the other hand, the study by Rauch et al. points out that complete radiologic response (by mammography and ultrasound) is not necessary in order for a patient to have pCR in the breast, since 63% of the patients who had pCR had some residual imaging abnormality presurgery (residual calcifications: 6; residual mass: 5; both: 1). Again, addition of breast MRI may have helped to identify some of the patients who achieved pCR despite persistent imaging abnormalities by mammography or breast ultrasound. The study by Rauch et al. included only triple-negative and HER2-positive patients. Although these breast cancer subtypes have considerably higher rates of pCR with currently used standard NAC regimens compared with the estrogen receptor (ER)-positive/HER2-negative subtype, the latter can also achieve pCR with NAC in about 10-20% of cases. 16, 17 Patients with ER-positive/HER2-negative breast cancer who are likely to have achieved pCR would also be candidates for future studies of omission of breast surgery if they could also be accurately identified by imaging modalities and VACB. It could be argued that addition of image-guided VACB for pCR prediction may be more important for patients with ER-positive/HER2-negative breast cancer versus those with triple-negative or HER2-positive disease, since there is evidence to suggest that imaging modalities are less accurate in predicting pCR in the former compared with the latter subtypes. Loo et al. 18 found that MRI changes during NAC correlated well with pathologic outcome in triple-negative and HER2-positive breast cancer but not in ER-positive/HER2-negative tumors. Similarly, De Los Santos et al., 19 in a multicenter study involving 746 patients, found that the negative predictive value of MRI was highest for patients who had triple-negative and HER2-positive breast cancer. Furthermore, among patients who achieved radiologic complete response, hormone-receptor positive status and low tumor grade were most commonly associated with residual disease at surgery, suggesting that radiologic complete response on preoperative MRI in these patient populations should be interpreted with caution. These findings further underscore that, if patients with ER-positive/HER2-negative subtype are to be included in trials of surgery omission after radiologic complete response to NAC, stereotactic VACB may play an even more important role in confirming the presence or absence of residual disease.
Some of the above questions will be addressed by currently ongoing and planned clinical trials, designed to evaluate in more detail the role of percutaneous biopsies in identifying patients at high likelihood for pCR after NAC. 15 In the USA, the NRG BR005 trial is currently accruing patients who achieve clinically complete and radiologic complete/near-complete response to NAC by trimodality breast imaging (mammography, ultrasound, and MRI). 15 After registration, patients undergo stereotactic vacuum-assisted core needle biopsy followed by breast-conserving surgery. The primary objective of the study is to assess the accuracy of post-NAC image-directed tumor bed biopsy for pCR, defined as resolution of both invasive disease and ductal carcinoma in situ. If successful, this study will supply important information for the conduct of future trials that will formally test omission of surgical resection of the tumor bed as a component of breast-conserving therapy. Secondary objectives of the study include evaluation of axillary nodal response to NAC and its relationship to breast pCR as well as correlation of imaging results with pathologic nodal status after NAC for future planning of axillary management in studies that will evaluate omission of breast surgery after NAC. The study also seeks to retrospectively assess the negative predictive value of a trimodality imaging algorithm in combination with tumor bed biopsy for predicting pCR, and to determine which combination of imaging studies best identifies the group achieving pCR. A total of 175 patients will be enrolled in the study.
Similar studies are also in development in Europe. Besides the NOSTRA Feasibility study, mentioned earlier, the MICRA trial 15 is a prospective, multicenter observational cohort study that will accrue 525 patients with radiologic complete or partial response on contrast-enhanced MRI. All tumor subtypes are eligible. After neoadjuvant systemic therapy (NST), eight ultrasoundguided biopsies are obtained in the region surrounding the marker, while the patient is under general anesthesia. Immediately thereafter, breast surgery will be performed and pathology results of the biopsies and resected specimens will be compared. The primary endpoint is specificity of post-NAC biopsies. In addition, sensitivity and positive and negative predictive value will be calculated.
The main goal of the above studies is to develop an optimal approach for appropriate selection of patients to be included in prospective trials evaluating omission of surgical resection of the breast tumor bed. If successful, this could lead to a major paradigm shift in breast cancer management from the current standard that dictates the necessity of breast tumor removal as part of the multidisciplinary approach.
